Patients with cystic fibrosis (CF) are at increased risk of venous thromboembolism, especially in association with central venous catheter use” Bansal and Ren (2016).
Patients with cystic fibrosis (CF) are at increased risk of venous thromboembolism, especially in association with central venous catheter use. Coumarin drugs and low molecular weight heparin are frequently used for anti-coagulant therapy, but are more challenging to administer in CF patients. Dabigatran, an oral thrombin antagonist, is an alternative anti-coagulant medication, but its use in CF has not been reported. We describe our experience in successfully using dabigatran for long-term anti-coagulation therapy in two CF patients. Our experience suggests that dabigatran can serve as an option for anticoagulation therapy in CF.
ReTweet if useful... Anti-coagulant therapy for cystic fibrosis patients with central venous access http://ctt.ec/Ped5E+ @ivteam #ivteam
Bansal, M. and Ren, C.L. (2016) Anti-coagulant therapy with dabigatran for cystic fibrosis patients. Pediatric Pulmonology. April 29th. [Epub ahead of print].
Thank you to our partners for supporting IVTEAM